KR101752484B1 - Composition for Treatment of Renal Cell Carcinoma and Beauty Expenses Composition Comprising Extract of Pharbitis Semen - Google Patents

Abstract

The present invention relates to a novel use of a white castor extract, and more particularly to a white castor ethanol extract comprising a composition for prevention and treatment of kidney cancer containing an extract of white shark ethanol as an active ingredient and a cosmetically acceptable cosmetic auxiliary additive As an active ingredient, to a composition for preventing kidney cancer. The composition and the cosmetic composition for treating renal cancer according to the present invention have an effect of inhibiting the growth of kidney cancer cells and inducing apoptosis, so that they can be effectively used for treatment and prevention of kidney cancer.

Description

TECHNICAL FIELD The present invention relates to a composition for treating renal cancer and a cosmetic composition,

The present invention relates to new uses of white castor oil extracts. Specifically, the present invention relates to a therapeutic composition and cosmetic composition comprising as an active ingredient a white castor extract exhibiting excellent prophylactic or therapeutic efficacy against renal cancer.

Among the major diseases of modern people, studies on the methods of treatment and diagnosis of cancer are proceeding mainly on lung cancer, liver cancer and stomach cancer which have a high incidence.

The kidney is an important urogenital organ that plays a role in excretion of waste products in the living body by filtering blood and generating urine. It is also an important endocrine organ that produces hormones such as angiotensin, which regulates blood pressure, and erythropoietin, which is an erythropoietic factor. There are two types of tumors that develop in the kidney: kindney cell cancers in adults, Wilms tumors in children, and sarcomas as rare tumors. Hereinafter, Renal cell carcinoma is called kidney cancer. The incidence of kidney cancer is about 2.5 per 100,000 population, and the male and female ratio is 2 to 3: 1, and it tends to be much for males. Among urological malignancies, prostate cancer and bladder cancer are followed by many tumors.

Although genetic factors are known as risk factors for kidney cancer, smoking and excessive fat intake are common. It is also known that the incidence of such tumors is high in patients undergoing long term dialysis. In kidney cancer, when the maximum diameter of the tumor is 5 ㎝ or less, any subjective symptoms are rare and often found by CT scan at the time of examination. Large tumors may have hematuria, abdominal tumors, and pain. In addition, systemic symptoms include fever, weight loss, anemia, and in some cases, erythrocyte hypertension, hypertension, hypercalcemia, etc. are caused by endocrine factors. On the other hand, the progression of the kidney cancer into the inferior vena cava may cause the vein of the abdominal surface to develop and the testicular varices may develop. Approximately 20% of kidney cancers are found from lung or bone metastases. In kidney cancer, the tendency of the tumor to spread in the vein is strong, and transition to other organs is likely to occur.

There are ultrasonography, CT, and angiography as the test methods for kidney cancer. However, since specific biochemical markers are not known, it is necessary to use a device. Although renal cancer can be classified into several pathologic categories, it is known that the cause of clear cell type renal cancer, which accounts for about 90% of the cases, is the deficiency of the von-Hippel-Lindau (VHL) gene . VHL gene deletion causes transcriptional activation of the hypoxic induction gene group through association disorder of HIF-α / VHF, and it is known that the expression of VEGF, TGFβ and the like is enhanced.

The main treatment for kidney cancer is surgery. Regardless of the stage of the disease, removal of the kidney or partial removal of the kidney is the most common case where removal is possible, and surgical removal of the kidney may be considered, even if metastasis is present. Methods other than surgical therapy include arterial embolization of the renal artery, which may be performed prior to surgery in cases where removal is not possible or when large tumors are removed. Recent advances in diagnostic imaging techniques have allowed kidney cancer to be detected early, even at very small sizes, with over 90% being cured in early cancer treatment. However, since the therapeutic outcome of large tumors larger than 5 cm or tumors with metastasis is poor (5 - year survival rate of the entire renal cell carcinoma is about 50 to 60%), the importance of early detection has been recognized.

On the other hand, Pharbitis Semen refers to seeds of white morning glory ( Pharbitis nil CHOISY), and the main ingredients are Pharbitin, Pharbitic acid, and tiglic acid. It is effective in the lungs, kidneys, large intestines, and through the feces, edema, sore throat, and lumbago (lumps in the stomach due to long body weight). It is said that it is good to put a leaf on the morning glory when it is cut by about 20 ㎝ from roots when it is attached with folk remedy, and it is said that it is good to put on the affected part by the water which it is when it is caught in the statue. Morning glory is native to tropical Asia, such as India, and is known to have about 256 varieties. Black seeds are also called black sharks and white seeds are called white sharks. The name Kim Jin means the shape of the seed, and the names of 盆 甑 and 狗 耳 are attached to the shape of the petal. It broke this medicine with a bit of smell and irritation, and the taste is worn, cold and venomous [poisonous and poisonous].

The shape of the bead is 4 ~ 6 vertically, and its outer surface is black ~ grayish brown or grayish white, smooth or slightly oval. In the magnifying glass, the outer surface of the seeds has short hairs, and the bottom of the ridge line is narrowed. The transverse surface is fan shaped and has a light yellowish brown to pale grayish brown color and the quality is dense. The seed coat is thin, its outer layer is dark gray, and the inner layer is light gray. Other names include black 牛, 耳 草, 白 牛 牛, 白 丑, 盆 甑 grass, 草 령), 黑 牛牛, . It is used when the body is swollen and has a strong diuretic effect and diuretic action, and the chronic pyelonephritis, cirrhosis and so on. It is effective for seawater, asthma, stubborn constipation, parasite removal. A strong subcutaneous effect has been reported with pharmacological action and intestinal peristalsis.

However, it has not yet been disclosed or disclosed in the above-mentioned literature in relation to diseases related to kidney cancer of white castor.

Accordingly, the inventors of the present invention completed the present invention by confirming that the extract of white castor oil can effectively kill kidney cancer cells while conducting herbal medicine against white shafts.

It is an object of the present invention to provide a composition for treating kidney cancer and a cosmetic composition containing an extract of castor oil as an active ingredient.

In order to accomplish the above object, the present invention provides a composition for preventing and treating renal cancer, which comprises an extract of Pharbitis Semen ethanol as an active ingredient.

The present invention also provides a cosmetic composition for the prevention of kidney cancer, which comprises an extract of Pharbitis Semen ethanol containing an cosmetically acceptable cosmetic auxiliary additive as an active ingredient.

Hereinafter, the present invention will be described in detail.

The present invention provides a composition for preventing and treating renal cancer, which comprises an extract of Pharbitis Semen ethanol as an active ingredient. The composition of the present invention comprises a castor oil extract as an active ingredient and may further comprise a pharmaceutically acceptable carrier or diluent.

In the composition for preventing and treating kidney cancer of the present invention, it is preferable that the ethanol extract is extracted for 24 hours at 50 DEG C, and the ethanol extract is more preferably dried and concentrated under reduced pressure at 45 DEG C, Most preferably 95%.

In addition, in the composition for preventing and treating kidney cancer of the present invention, it is preferable that the renal cancer is a kindney cell cancer.

The white shark extract of the present invention can be applied to any part of the white shark, but is preferably extracted from white shark. The extraction solution can be obtained by extraction with water or an organic solvent. Examples of the organic solvent include lower alcohol, acetone, chloroform, methylene chloride, ether, ethyl acetate, hexane and the like. As the lower alcohol, methanol, ethanol, propanol and butanol can be mentioned, and ethanol is most preferable.

Concretely, 95 to 90% ethanol is added to the dried or powdered product 1 to 5 times, preferably 3 times, at a temperature of 20 to 100 ° C, preferably 40 to 60 ° C for 10 to 100 hours, 40 hours, more preferably 24 hours, and then filtered to produce an ethanol extract of the white shark. Preferably, the extract is filtered, and the resulting filtrate is concentrated under reduced pressure. In the above extraction methods, the extraction process may be repeated twice or more as necessary, and the extract obtained after filtration may be lyophilized or dried under reduced pressure to a powder form.

The term "pharmaceutically acceptable carrier" is intended to encompass pharmaceutically acceptable substances, such as liquid or solid fillers, diluents, excipients or solvents, which serve to transport the active ingredient from one or more parts of the body to other organs or parts of the body , Composition or vehicle.

The composition for the treatment of renal cancer of the present invention may be prepared from a medicament by adding one or more pharmaceutically acceptable carriers together with an active ingredient. Such carriers include, but are not limited to, saline, buffered saline, water, glycerol, and ethanol, and any suitable formulation known in the art (Remington's Pharmaceutical Science (recent edition), Mack Publishing Company, Easton PA) .

The pharmaceutical composition of the present invention can be administered orally in clinical administration and can be used in the form of a general pharmaceutical preparation. In the case of pharmaceutical preparation, the filler, extender, binder, wetting agent, A surfactant, or the like. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like. Examples of liquid formulations for oral use include suspensions, solutions, emulsions and syrups. Common diluents such as water, In addition to liquids and paraffins, various excipients such as wetting agent sweetening agents, perfumes, preservatives and the like may be included.

In addition, the herbal medicine which may be added to the composition of the present invention may be any pharmaceutically acceptable herbal medicine, for example, Angelicae tenuissimae Radix, Gastrodiae Rhizoma, Bapleuri Radix, (Rhizoma), Angelicae gigantis Radix, Persicae Semen, Cinnamomi Ramulus, Rhei Rhizoma, Glycyrrhizae Radix, Cnidii Rhizoma, Aurantii nobilis Pericarpium, Alismatis Rhizoma, Coptidis Rhizoma, Scutellariae Radix, Hoelen, Paeoniae Radix, Atractylodis Rhizoma alba, Phellodendri Cortex, Gardeniae Fructus, Pinelliae Tuber, Uncaria Ramuluset, Uncus, Ponciri Fructus, Ginseng, Liriopis Tuber, Polygalae Radix, Acori graminei Rhizoma, Atractylodis Rhizoma alba, Chrysanthemi Flos, Ledebouriellae Radix, ), Ginger (Zingiberis Rhizoma crudus), ganoderma (Natrii sulfas), control yphi Fructus, Salviae Radix, Mautan Radicis Cortex, Rehmanniae Radix, Menthae Herba, Dioscoreae Rhizoma, Polyporus, Polygonimultiflori Radix, Allii tuberosi Semen, Cassiae Semen, Lycii Fructus, Araliae cordatae Radix, Eucommiae Cortex, Hedyotis Herba, Saururus Herba, Artemisiaecapillaris Herba, Anemarrhenae, Rhizoma, Rhizoma, Carthami Flos, Astragali Radix, Lycopodium, Ginkgonis Folium, Polygonati Rhizoma, Nelumbinis Semen, Fossilia ossis Mastodi, Lycii radicis Cortex ), Achyranthis Radix, Rehmanniae Radix preparata, Perillae Semen, Thujae Semen, Hordei Fructus germinatus, Cuscutae Semen, Morindae Radix, Pini koraiensis Radix) may be used alone or in combination.

The composition of the present invention can be administered in various forms of parenteral administration at the time of actual clinical administration. Solid formulations include tablets, pills, powders, granules, capsules and the like. Examples of the liquid formulations include suspensions, , Syrups, and the like. Various excipients such as wetting agent sweeteners, fragrances, preservatives, etc. may be included in addition to simple diluents commonly used in water, liquids and paraffins. Specifically, formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like. Calcium or vitamin D ₃ may also be added to enhance the efficacy of the therapeutic agent. Such compositions may be presented in unit-dose (one-time) or multi-dose (several-dose) containers, such as sealed ampoules and vials, and may be presented in a sterile liquid carrier, Lt; RTI ID = 0.0 > freeze-drying < / RTI > Immediate injectable solutions and suspensions may be prepared from sterile powders, granules and tablets.

The formulations of the present invention may be applied differently depending on the age, sex, condition of the subject, the degree of absorption of the active ingredient in the body, the rate of inactivation and the rate of excretion, and the drugs used in combination. The present invention also includes formulations of dosage units. The formulations are presented in separate dosage forms, such as tablets, coated tablets, capsules, pills, suppositories, and ampoules, and the content of active compound in the drug is a fraction or multiple of the individual dosage. Dosage units may contain, for example, 1, 2, 3 or 4 times, or 1/2, 1/3 or 1/4 times the individual doses. The individual doses preferably contain amounts in which the active compound is administered in a single dose, which usually corresponds to the full, half, one-third or one-fourth of the daily dose.

As used herein, the term "extract " means an active ingredient isolated from a natural product. The extract can be obtained by an extraction process using water, an organic solvent, or a mixed solvent thereof, and includes an extract, a dry powder thereof, or all the forms formulated with it.

In a specific embodiment of the present invention, the ethanol extract of Paeonia japonica kills 98.8% of ACHN kidney cancer cells at 100 μg / ml and the IC ₅₀ (half maximal inhibitory concentration) was 10.5 μg / ml. The above results demonstrate that the white castor extract of the present invention has an excellent ACHN kidney cancer cell killing activity and further has a kidney cancer treatment and prevention activity.

As used herein, the term "prevention" means any act that inhibits or delays the onset of renal cancer by administration of the composition.

In the present invention, the term "treatment" means any action that improves or alters the symptom of renal cancer by administration of the composition.

In the present invention, the white castor extract can be extracted and used by using water, an organic solvent, or a mixed solvent thereof. Preferably an organic solvent, especially ethanol. The extracted liquid can be used directly or by concentrating and / or drying. In the case of extraction using an organic solvent, an organic solvent such as methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N-dimethylformamide (DMF) (DMSO), 1,3-butylene glycol, propylene glycol, or a mixed solvent thereof. The active ingredient of the herbal medicine may be extracted at room temperature or warmed under the condition that the active ingredient is not destroyed or minimized. Depending on the organic solvent to be extracted, the degree of extraction and the degree of loss of the active ingredient of the medicament may differ. Therefore, an appropriate organic solvent should be selected and used. The extraction method is not particularly limited, and examples thereof include cold extraction, ultrasonic extraction, and reflux cooling extraction. Filtration is a process of removing suspended solid particles from an extract, and may be performed by filtering particles using a cotton, nylon, or the like, or by ultrafiltration, freezing filtration, centrifugation, and the like.

Concentration of the extract can be carried out by reduced-pressure concentration, reverse osmosis concentration, or the like. The post-concentration drying step includes, but is not limited to, freeze drying, vacuum drying, hot air drying, spray drying, vacuum drying, foam drying, high frequency drying, infrared drying and the like. In some cases, a step of pulverizing the final dried extract may be added.

In addition, the extract may be subjected to an additional fractionation process. Preferably, the extract is suspended in distilled water, and the non-polar solvent soluble layer is extracted and separated by using a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate, or a mixed solvent thereof , Which can be used by concentration and / or drying.

In the present invention, the term "pharmaceutically acceptable salt" means salts derived from pharmacologically or physiologically acceptable inorganic acids, organic acids and bases. Examples of suitable acids include hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene- Formic acid, benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and the like. Salts derived from suitable bases may include alkali metals, such as sodium, alkaline earth metals, such as magnesium, ammonium, and the like.

The pharmaceutical composition for the prevention and treatment of kidney cancer diseases according to the present invention comprises 0.1 to 50% by weight of the above extract or compound, based on the total weight of the composition. In addition, the composition does not increase the efficacy, but may contain additional ingredients that are commonly used in pharmaceutical compositions to improve odor, taste, visual appearance, and the like. In addition, the composition may further comprise inorganic and organic additives such as vitamins B1, B2, B6, C, E, niacin, carnitine, betaine, folic acid pantothenic acid, biotin, zinc, iron, calcium, chromium, magnesium, As shown in FIG. In addition, the composition may contain a substance that has therapeutic activity against kidney cancer used alone or in a previously used form.

The term "patient" in the present invention refers to a disease caused by kidney cancer and its direct or indirect cause, and can be administered to humans, horses, sheep, pigs, , Nutrition, and dogs. By administering to a patient a composition comprising the extract of the present invention, the kidney cancer mentioned above can be effectively prevented and treated. The composition of the present invention may be administered in parallel with the existing renal cancer therapeutic agent.

The term "administering" in the present invention means introducing a predetermined substance into a patient in any appropriate manner, and the administration route of the composition of the present invention may be oral or parenteral ≪ / RTI > The composition may also be administered by any device capable of transferring the active agent to the target cell.

The composition of the present invention is administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" as used herein means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level will depend on the sex of the patient, age, , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including co-administered drugs, and other factors well known in the medical arts. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. May be administered singly or multiply. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without adverse effect, and can be easily determined by those skilled in the art. The method for administration of the composition comprising the extract or the compound prepared according to the preparation method of the present invention is preferably oral or intravenous. Generally, the effective dose is usually 1 to 10 times, 500 mg / kg is preferable, and in case of intravenous administration, 1 to 100 mg / kg is preferable, and it can be administered 2-3 times a day. The dosage level for a particular patient can be varied depending on the sex, age, health condition, diet, time of administration, method of administration, drug mix, patient condition, and severity of neurological disease.

The present invention also provides a cosmetic composition for the prevention of kidney cancer, which comprises an extract of Pharbitis Semen ethanol containing an cosmetically acceptable cosmetic auxiliary additive as an active ingredient.

The cosmetic composition of the present invention preferably contains 0.01 to 10% by weight, more preferably 0.1 to 1% by weight, of the ethanol extract in the total weight. The cosmetic composition of the present invention is not particularly limited in its formulation and may have cosmetic formulations of softening agent, nutritional lotion, massage cream, nutritional cream, pack, gel or skin adhesive type, Ointments, gels, creams, patches or spray formulations.

In the present invention, it was confirmed that ACHN cells were killed when ACHN kidney cancer cells were injected with the white castor extract of the present invention (see FIG. 1 ). Therefore, it can be newly found that the extract of Ganoderma lucidum is effective for the treatment of kidney cancer. Thus, in the present invention, the present invention was completed by preparing a cosmetic composition for the prevention of kidney cancer containing an extract of Paeonia japonica as an active ingredient (see Production Example 2 ).

As described above, the extract of Ganoderma lucidum according to the present invention inhibits the growth of kidney cancer cells and induces apoptosis. Therefore, the composition for treating renal cancer according to the present invention will be very effective for the treatment of patients with kidney cancer.

FIG. 1 shows the results of Alamar Blue analysis to examine the influence of the introduction of white shafts on the growth of renal cancer cells in human renal cancer cells, ACHN cells, wherein the X-axis is the concentration of the white algae extract and the Y- Lt; / RTI >

Hereinafter, the present invention will be described in more detail based on the following examples. It should be noted, however, that the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The present invention is not limited to the following examples. Will be apparent to those skilled in the art to which the present invention pertains.

≪ Example 1 > Preparation of white castor oil extract

3 kg of white shrimp (Chinese origin) purchased from Seoul Medicinal Plant was dried and pulverized for 5 days at shade and room temperature. The ground shrub was immersed in 30 L of 95% ethanol and extracted at 50 DEG C for 24 hours. This was filtered through a filter paper, dried and concentrated under reduced pressure at 45 캜 to obtain 315 g of a total extract, which was stored at -20 캜.

<Example 2> Effect of white algae extract on growth of kidney cancer cells

In order to examine the effect of the extract of Ganoderma lucidum extract obtained from Example 1 on the growth of kidney cancer cells, ACHN cells as human kidney cancer cells were treated with ethanol extract of white shark for 48 hours and analyzed by Alamar Blue. The Alamar Blue assay is a modified form of MTT assay that measures the fluorescence intensity of a product after degradation of a compound that is degraded by a specific enzyme into a living cell to determine the relative number of living cells after treatment It is an experimental method. This will be described in more detail below.

&Lt; 2-1 > Preparation and treatment of human kidney cancer cell line

The kidney cancer cell line ACHN cells used in the present invention were purchased from Korean Cell Line Bank (KCLB) and used for the experiment. Specifically, ACHN kidney cancer cells were cultured in MEM (Minimum essential medium) containing 10% FBS (fetal bovine serum) (Welgene) and 25 mM HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid) And subcultured in the medium.

<2-2> Measurement of cell growth inhibition of ACHN kidney cancer cells

The effect of the extract of the white castor oil extracted in Example 1 on the growth of ACHN cells, which are kidney cancer cells, was confirmed. Specifically, 6.0 X 10 ³ ACHN kidney cancer cells were seeded into each well of a 96-well plate and cultured for 24 hours. Then, the cells were cultured in DMSO (dimethyl sulfoxide) Ethanol extract was treated for 48 hours at a concentration of 0 to 100 μg / ml (specifically, 0, 3.125, 6.25, 12.5, 25, 50 and 100 μg / ml, respectively) (Table 1). After treating each concentration of the extract, 20 μl of Alamar Blue reagent was added to 0.2 ml of the cell culture solution filled in each well in a 96-well plate, and the plate was cultured in an incubator for 2 hours. The plate was slowly shaken to react cells in each well, and the intensity of fluorescence was measured at 590 nm using a fluorescence photometer (Molecular Devices Corp.) while irradiating light with a wavelength of 544 nm. 1 is shown in Fig.

Concentrate concentration Kidney cancer cell viability (average) Standard Deviation 0 [mu] g / ml 1,000 0.000 3.125 [mu] g / ml 1.004 0.008 6.25 [mu] g / ml 0.892 0.035 12.5 占 퐂 / ml 0.331 0.025 25 [mu] g / ml 0.068 0.003 50 [mu] g / ml 0.021 0.001 100 [mu] g / ml 0.012 0.001

As a result, as shown in Table 1 and Fig. 1, the growth of kidney cancer cells was decreased as the treatment concentration of white shafts was higher, and it was found that the white shafts had the effect of treating kidney cancer. Kidney cancer cells were killed at 10.8% at 6.25 ㎍ / ㎖, 66.9% at 12.5 ㎍ / ㎖, 93.2% at 25 ㎍ / ㎖, 97.9% at 50 ㎍ / ㎖ and 98.8% at 100 ㎍ / ㎖. In addition, IC ₅₀ (half maximal inhibitory concentration) was measured at 10.5 / / ml. In Table 1, the number of survival cells of kidney cancer cells in the control group not treated with sham-axes was expressed as 1, and the relative number of cells of renal cancer cells after 48 hours according to each sham treatment concentration was described. Thus, the extract of the present invention has excellent ACHN cell killing activity, further demonstrating that it has kidney cancer treatment and prevention activity.

&Lt; Example 3 > Acute Toxicity Test with White Extract Extract

The white shafts used in the present invention were widely used as medicines, and thus it was considered that there would be no problem in stability. To confirm the toxicity test at the time of oral administration and intraperitoneal administration.

Acute toxicity tests were carried out using 6-week-old SPF SD rats. Animals of two groups each were suspended in 0.5% methylcellulose solution of the extract of the present invention in Example 1, and the suspension was administered once orally at a dose of 5 g / kg. After the administration of the test substance, the mortality, clinical symptoms, and weight changes of the animals were observed, and hematological tests and blood biochemical tests were carried out, and autopsy was performed to observe the abnormalities of the abdominal organs and thoracic organs.

As a result of the test, there were no clinically symptomatic or dead animals in all the animals to which the test substance was administered, and no toxic change was observed in weight change, blood test, blood biochemical test, and autopsy findings. These results baekchuk extract does not show all of the toxic change in rats up to 5 g / ㎏ minimum oral lethal dose (LD ₅₀₎ was determined to be a safe substance less than 5 g / ㎏.

<Preparation Example 1> Preparation of a therapeutic agent for renal cancer containing an extract of Paeonia japonica as an active ingredient

The inventors of the present invention confirmed that the extract of Paeonia japonica was excellent in the efficacy of treating the kidney cancer through the above examples, and thus a therapeutic agent for renal cancer containing the extract as an active ingredient was prepared as follows. The preparation examples of the following therapeutic agents can be applied not only to therapeutic agents but also to the production of cosmetic compositions.

&Lt; 1-1 > Soft gelatin capsules (wt.%)

White castor oil extract 20%

Vitamin C 4.5%

Vitamin D ₃ 0.001%

Manganese sulfate 0.1%

Wax 10%

Palm oil 25%

Safflower oil 30.399%

 &Lt; 1-2 > Preparation of an intravenous agent preparation containing white castor extract (% by weight)

White shark extract 0.2%

Mannitol 0.3%

Physiological saline 9.5%

&Lt; 1-3 > Tablets (wt%) containing white castor extract

White shark extract 35%

Vitamin C 10%

Vitamin D ₃ 0.001%

Manganese sulfate 0.1%

Crystalline cellulose 25.0%

Lactose 17.999%

Magnesium stearate 2%

&Lt; Preparation Example 2 > Preparation of a cosmetic composition containing an extract of white castor oil as an active ingredient

The inventors of the present invention confirmed that the extract of Paeonia japonica was excellent in the treatment of kidney cancer through the above examples and prepared a cosmetic composition containing it as an active ingredient as follows.

&Lt; 2-1 > Nutritional lotion containing (% by weight)

Nutrition lotion was prepared according to a conventional method according to the composition described below.

Glycerin 8.0%

Butylene glycol 4.0%

Hyaluronic acid extract 5.0%

Beta-glucan 7.0%

Carbomer 0.1%

White shark extract 0.05%

Capphilic / capric triglyceride 8.0%

Squalane 5.0%

Cetearyl glucoside 1.5%

Sorbitan stearate 0.4%

Cetearyl alcohol 1.0%

Triethanolamine 0.1%

Purified water balance

&Lt; 2-2 > Nutrition Cream Containing White Extract (wt%)

Nutrition creams were prepared in a conventional manner according to the compositions described below.

Glycerin 3.0%

Butylene glycol 3.0%

Liquid paraffin 7.0%

Beta-glucan 7.0%

Carbomer 0.1%

100%

Cappylic / capric triglyceride 3.0%

Squalane 5.0%

Cetearyl glucoside 1.5%

Sorbitan stearate 0.4%

Polysorbate 60 1.2%

Triethanolamine 0.1%

Purified water balance

&Lt; 2-3 > Massage cream (% by weight)

Massage creams were prepared in a conventional manner according to the compositions described below.

Glycerin 8.0%

Butylene glycol 4.0%

Liquid paraffin 45.0%

Beta-glucan 7.0%

Carbomer 0.1%

White shark extract 1.0%

Cappylic / capric triglyceride 3.0%

Waste 4.0%

Cetearyl glucoside 1.5%

0.9% sorbitan sesquioleate

Vaseline 3.0%

Paraffin 1.5%

Purified water balance

&Lt; 2-4 > Pack (wt%) containing white castor extract

The pack was prepared in a conventional manner according to the composition described below.

Glycerin 4.0%

Polyvinyl alcohol 15.0%

Hyaluronic acid extract 5.0%

Beta-glucan 7.0%

Allantoin 0.1%

White shark extract 0.5%

Nonyl phenyl ether 0.4%

Polysorbate 60 1.2%

Ethanol 6.0%

Purified water balance

&Lt; 2-5 > Ointment of external preparation for skin containing white castor oil extract (% by weight)

Ointments were prepared in a conventional manner according to the composition described below.

Glycerin 8.0%

Butylene glycol 4.0%

Liquid paraffin 15.0%

Beta-glucan 7.0%

Carbomer 0.1%

100%

Squalane 1.0%

Cetearyl glucoside 1.5%

Sorbitan stearate 0.4%

Cetearyl alcohol 1.0%

Waste 4.0%

Purified water balance

It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the invention, and are not intended to limit the scope of the invention. .

Claims (7)

A composition for preventing and treating renal cancer, comprising an extract of Pharbitis Semen ethanol as an active ingredient.
The composition for preventing and treating renal cancer according to claim 1, wherein the ethanol extract is extracted at 50 캜 for 24 hours and dried and concentrated under reduced pressure at 45 캜.
delete delete The composition for preventing and treating renal cancer according to claim 1, wherein the composition comprises a pharmaceutically acceptable carrier or diluent.
delete delete

Images